In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From AlphaCore Pharma

Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell

Actavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.

BioPharmaceutical Deals

Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues

As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.

BioPharmaceutical Business Strategies

AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub

Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.

BioPharmaceutical Sweden

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.

BioPharmaceutical Japan
See All

Company Information

UsernamePublicRestriction

Register